TrialSignal
Clinical trial intelligence report
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01583283-Jul 28, 2026
NCT ID
NCT01583283
Status
COMPLETED
Phase
PHASE1
Sponsor
Celgene
Executive brief
Investment-Ready Snapshot
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma is a PHASE1 clinical asset sponsored by Celgene in Multiple Myeloma. SEO and diligence focus: ACY-1215, lenalidomide, Dexamethasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01583283
Indication
Multiple Myeloma
Modality
small molecule
Target
ACY-1215, lenalidomide, Dexamethasone
Intervention
ACY-1215, lenalidomide, Dexamethasone
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.